Clinical trials: Post Menopausal
Acute Ovarian Failure, Infertility
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Background: Medical advances have improved survival rates for many cancers and other illnesses. This means that more people are coping with the long-term effects of these treatments. Some treatments can cause female infertility.
- Conditions
- Acute Ovarian Failure, Infertility, Early Menopause And Infertility In Females After Treatment For Childhood Cancer
- Trial name
- NCT05440617
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Healthy
Estrogen Alternatives Study
Healthy postmenopausal women not currently taking hormone replacement or hormone modulating therapy take a 3-month course of estradiol/raloxifene/placebo to evaluate the effects of each on vascular function, as indicated by PET…
- Trial name
- NCT00108238
- Testing
- Estradiol followed by progesterone, Raloxifene
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Menopause, Hormone Replacement Therapy, Post-Menopausal
Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy
This study is conducted in Europe. The aim of this study is to verify the therapeutic effects of low-dose hormone replacement therapy (HRT) in female patients over adequately long time period in normal clinical practice…
- Trial name
- NCT01487304
- Testing
- Marketed low dose hormone replacement therapy
- Where
- Czechia
- Volunteers
- 3,760 people
- Sponsor
- Novo Nordisk A/S
Cardiovascular Diseases, Overweight
Enhancing Mental and Physical Health of Women Veterans 3.0
Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that…
- Conditions
- Cardiovascular Diseases, Overweight, Obesity, Hypertension
- Trial name
- EMPOWER (NCT07356479)
- Testing
- EBQI Booster (EBQI/B), EBQI Booster + External Facilitation (EBQI/B+EF)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- VA Office of Research and Development
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550…
- Trial name
- NCT00551174
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 781 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen with or without octreotide may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002864
- Testing
- octreotide acetate, tamoxifen citrate
- Where
- 40 sites in United States, Canada
- Volunteers
- 667 people
- Sponsor
- NCIC Clinical Trials Group
Non-Small Cell Lung Cancer
Exemestane in Post-Menopausal Women With NSCLC
This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab…
- Trial name
- NCT02666105
- Testing
- Exemestane
- Where
- 18 sites in United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Osteoporosis
Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)
In this survey, to collect the safety and efficacy information of Bazedoxifene in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined…
- Trial name
- VIOLINE (NCT01470326)
- Testing
- Bazedoxifene
- Volunteers
- 3,187 people
- Sponsor
- Pfizer
Breast Cancer
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00931450
- Testing
- exemestane, sunitinib malate
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Institut Català d'Oncologia
Post Menopausal Osteoporosis
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study.
- Trial name
- NCT00545090
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 17 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 561 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
The purpose of this survey is to describe long-term tolerance as seen under current conditions of use for anastrozole.
- Trial name
- ARIES (NCT00542594)
- Volunteers
- 1,840 people
- Sponsor
- AstraZeneca
Postmenopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or…
- Trial name
- NCT02604836
- Testing
- Ibandronate
- Where
- 142 sites in United States
- Volunteers
- 1,711 people
- Sponsor
- Hoffmann-La Roche
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of tumor cells. Hormone therapy using therapeutic estradiol may fight breast cancer by lowering the amount of estrogen the body makes.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01385280
- Testing
- therapeutic estradiol, exemestane, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Arizona
Osteoporosis in Post-menopausal Women
Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women
Multicentered, randomized study of safety and efficacy of whole-body vibration (WBV) as add on to standard pharmacological treatment of osteoporosis (alendronate 70 mg/ week or raloxifene 60 mg/day) in post-menopausal women.
- Trial name
- NCT01415050
- Testing
- Whole body vibration
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- X-pert Med GmbH
Breast Cancer
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are…
- Trial name
- NCT00259090
- Testing
- Fulvestrant, Anastrazole
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Hysterectomy
Post-Hysterectomy Nursing Support Program
Objective: This study was conducted to evaluate the effectiveness of the nursing support program developed for women undergoing hysterectomy.
- Trial name
- NCT05063864
- Testing
- Nursing Support Program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Suleyman Demirel University
Primary Hyperparathyroidism, Bone Disease
Bone Architectural Parameters in Postmenopausal Women Affected With Primary Hyperparathyroidism
Bone lesions are frequent in primary hyperparathyroidism (PHPT). Conventional measurement by Dual-Energy X-ray Absorptiometry does not provide enough information about the bone impact of excessive parathyroid hormone (PTH)…
- Trial name
- MicrOs (NCT02539498)
- Testing
- HR-pQCT
- Where
- 3 sites in France
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer, Menopausal Symptoms
Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer
RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It is not yet known if hormone replacement therapy increases the risk of breast cancer recurrence in women previously treated for early…
- Trial name
- NCT00003771
- Testing
- therapeutic estradiol, norethindrone acetate
- Where
- 6 sites in Finland, Norway and 3 more
- Volunteers
- 1,300 people
- Sponsor
- Regional Oncologic Center
Post Menopausal Osteoporosis
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when…
- Trial name
- NCT01674621
- Testing
- Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg)
- Where
- 9 sites in United States, Denmark and 2 more
- Volunteers
- 250 people
- Sponsor
- Radius Health, Inc.
Breast Cancer
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
The primary objective of this trial is to evaluate the effect of the addition of a 2 year, centrally delivered individualized, telephone-based lifestyle intervention focusing on weight management to a mailed educational…
- Trial name
- LISA (NCT00463489)
- Testing
- Lifestyle intervention, Mail-based
- Where
- 21 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)